The third potential explanation for the mixed results on poor CYP2D6 metabolism is the use of DNA from different sources in different studies.39 Two trials have previously reported a null association between poor CYP2D6 metabolism and breast cancer outcomes.8,9 However, the validity of the two studies has been questioned because those trials used tumor DNA.39 This evidence concerns the gene CYP2D6 and neoplasm.